Premium
Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice
Author(s) -
Perera Vidya,
Bies Robert R.,
Mo Gary,
Dolton Michael J.,
Carr Vaughan J.,
McLachlan Andrew J.,
Day Richard O.,
Polasek Thomas M.,
Forrest Alan
Publication year - 2014
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.12410
Subject(s) - ziprasidone , perphenazine , quetiapine , olanzapine , aripiprazole , risperidone , population , therapeutic drug monitoring , antipsychotic , clozapine , pharmacokinetics , medicine , pharmacology , schizophrenia (object oriented programming) , psychiatry , environmental health
Aim To determine optimal sampling strategies to allow the calculation of clinical pharmacokinetic parameters for selected antipsychotic medicines using a pharmacometric approach. Methods This study utilized previous population pharmacokinetic parameters of the antipsychotic medicines aripiprazole, clozapine, olanzapine, perphenazine, quetiapine, risperidone (including 9‐ OH risperidone) and ziprasidone. d ‐optimality was utilized to identify time points which accurately predicted the pharmacokinetic parameters (and expected error) of each drug at steady‐state. A standard two stage population approach ( STS ) with MAP ‐Bayesian estimation was used to compare area under the concentration–time curves ( AUC ) generated from sparse optimal time points and rich extensive data. Monte Carlo Simulation ( MCS ) was used to simulate 1000 patients with population variability in pharmacokinetic parameters. Forward stepwise regression analysis was used to determine the most predictive time points of the AUC for each drug at steady‐state. Results Three optimal sampling times were identified for each antipsychotic medicine. For aripiprazole, clozapine, olanzapine, perphenazine, risperidone, 9‐ OH risperidone, quetiapine and ziprasidone the CV% of the apparent clearance using optimal sampling strategies were 19.5, 8.6, 9.5, 13.5, 12.9, 10.0, 16.0 and 10.7, respectively. Using the MCS and linear regression approach to predict AUC , the recommended sampling windows were 16.5–17.5 h, 10–11 h, 23–24 h, 19–20 h, 16.5–17.5 h, 22.5–23.5 h, 5–6 h and 5.5–6.5 h, respectively. Conclusion This analysis provides important sampling information for future population pharmacokinetic studies and clinical studies investigating the pharmacokinetics of antipsychotic medicines.